Shopping Cart 0
Cart Subtotal
USD 0

AmpliPhi Biosciences Corp (APHB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

AmpliPhi Biosciences Corp (AmpliPhi) is a biotechnology company which focuses on development and commercialization of bacteriophage-based antibacterial therapeutics. The company by utilizing its proprietary bacteriophage technology developed a pipeline of products for the treatment of various antibiotic-resistant bacterial infections. Its pipeline product portfolio includes AB-SA01 for Staphylococcus aureus (S. aureus) infections including methicillin-resistant S. aureus and AB-PA01 for Pseudomonas aeruginosa lung infections in cystic fibrosis patients. It has manufacturing facility in Ljubljana, Slovenia; and a laboratory in Richmond, Virginia and Brookvale, Australia. AmpliPhi is headquartered in San Diego, California, the US.

AmpliPhi Biosciences Corp (APHB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

AmpliPhi Biosciences Acquires Certain Bacteriophage Assets from Novolytics 13

Partnerships 14

AmpliPhi Biosciences to Enter into Agreement with WSLHD and Westmead Institute for Medical Research 14

AmpliPhi Biosciences Enters into Cooperative Research and Development Agreement with US Department of Veterans 15

AmpliPhi Biosciences Enters into Agreement with University of Adelaide 16

AmpliPhi BioSciences Enters Into R&D Agreement With U.S. Army Medical Research and Materiel Command And Walter Reed Army Institute of Research 17

Licensing Agreements 18

AmpliPhi Biosciences Enters into License Agreement with Takara Bio 18

AmpliPhi Enters into Licensing Agreement with University of Leicester 19

Equity Offering 20

AmpliPhi Biosciences Raises USD6.8 Million in Public Offering of Shares 20

AmpliPhi Biosciences Raises USD3 Million in Private Placement of Shares 22

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares 23

AmpliPhi Biosciences Files Registration Statement for Public Offering of Shares 24

AmpliPhi Biosciences Raises USD10.6 Million in Public Offering of Shares 25

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares and Warrants 27

AmpliPhi BioSciences Raises USD5 Million in Public Offering of Shares and Warrants 29

AmpliPhi BioSciences Raises USD13 Million in Private Placement of Shares 31

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 18 Million 32

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 7 Million 33

Debt Offering 35

Ampliphi Biosciences Completes Private Placement Of Notes For USD 0.5 Million 35

Acquisition 36

AmpliPhi Biosciences Completes Acquisition Of Special Phage, Developer Of Anti-Bacterial Therapies 36

AmpliPhi Biosciences Corp-Key Competitors 37

AmpliPhi Biosciences Corp-Key Employees 38

AmpliPhi Biosciences Corp-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Aug 09, 2018: AmpliPhi Biosciences reports second quarter 2018 financial results and business highlights 40

May 15, 2018: AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights 41

Mar 14, 2018: AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights 42

Nov 14, 2017: AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights 43

Aug 14, 2017: AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights 44

May 15, 2017: AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights 46

Mar 27, 2017: AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights 48

Corporate Communications 50

May 31, 2017: AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer 50

Jan 30, 2017: AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer 51

Government and Public Interest 52

Sep 06, 2017: AmpliPhi Biosciences Announces Receipt of USD 2.0 Million R&D Tax Incentive 52

Product News 53

01/03/2018: AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 53

Clinical Trials 54

Sep 11, 2017: AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus 54

Apr 17, 2017: AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal 55

Apr 04, 2017: AmpliPhi Biosciences Presents Clinical and Preclinical Data of Pipeline Program AB-SA01 at Two Scientific Conferences 56

Other Significant Developments 57

Dec 14, 2017: AmpliPhi Biosciences Provides Corporate and Strategic Update 57

May 01, 2017: AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AmpliPhi Biosciences Corp, Deals By Therapy Area, 2012 to YTD 2018 9

AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AmpliPhi Biosciences Acquires Certain Bacteriophage Assets from Novolytics 13

AmpliPhi Biosciences to Enter into Agreement with WSLHD and Westmead Institute for Medical Research 14

AmpliPhi Biosciences Enters into Cooperative Research and Development Agreement with US Department of Veterans 15

AmpliPhi Biosciences Enters into Agreement with University of Adelaide 16

AmpliPhi BioSciences Enters Into R&D Agreement With U.S. Army Medical Research and Materiel Command And Walter Reed Army Institute of Research 17

AmpliPhi Biosciences Enters into License Agreement with Takara Bio 18

AmpliPhi Enters into Licensing Agreement with University of Leicester 19

AmpliPhi Biosciences Raises USD6.8 Million in Public Offering of Shares 20

AmpliPhi Biosciences Raises USD3 Million in Private Placement of Shares 22

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares 23

AmpliPhi Biosciences Files Registration Statement for Public Offering of Shares 24

AmpliPhi Biosciences Raises USD10.6 Million in Public Offering of Shares 25

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares and Warrants 27

AmpliPhi BioSciences Raises USD5 Million in Public Offering of Shares and Warrants 29

AmpliPhi BioSciences Raises USD13 Million in Private Placement of Shares 31

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 18 Million 32

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 7 Million 33

Ampliphi Biosciences Completes Private Placement Of Notes For USD 0.5 Million 35

AmpliPhi Biosciences Completes Acquisition Of Special Phage, Developer Of Anti-Bacterial Therapies 36

AmpliPhi Biosciences Corp, Key Competitors 37

AmpliPhi Biosciences Corp, Key Employees 38

AmpliPhi Biosciences Corp, Other Locations 39

AmpliPhi Biosciences Corp, Subsidiaries 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AmpliPhi Biosciences Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

AmpliPhi Biosciences Corp (AmpliPhi) is a biotechnology company which focuses on development and commercialization of bacteriophage-based antibacterial therapeutics. The company by utilizing its proprietary bacteriophage technology developed a pipeline of products for the treatment of various antibiotic-resistant bacterial infections. Its pipeline product portfolio includes AB-SA01 for Staphylococcus aureus (S. aureus) infections including methicillin-resistant S. aureus and AB-PA01 for Pseudomonas aeruginosa lung infections in cystic fibrosis patients. It has manufacturing facility in Ljubljana, Slovenia; and a laboratory in Richmond, Virginia and Brookvale, Australia. AmpliPhi is headquartered in San Diego, California, the US.

AmpliPhi Biosciences Corp (APHB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

AmpliPhi Biosciences Acquires Certain Bacteriophage Assets from Novolytics 13

Partnerships 14

AmpliPhi Biosciences to Enter into Agreement with WSLHD and Westmead Institute for Medical Research 14

AmpliPhi Biosciences Enters into Cooperative Research and Development Agreement with US Department of Veterans 15

AmpliPhi Biosciences Enters into Agreement with University of Adelaide 16

AmpliPhi BioSciences Enters Into R&D Agreement With U.S. Army Medical Research and Materiel Command And Walter Reed Army Institute of Research 17

Licensing Agreements 18

AmpliPhi Biosciences Enters into License Agreement with Takara Bio 18

AmpliPhi Enters into Licensing Agreement with University of Leicester 19

Equity Offering 20

AmpliPhi Biosciences Raises USD6.8 Million in Public Offering of Shares 20

AmpliPhi Biosciences Raises USD3 Million in Private Placement of Shares 22

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares 23

AmpliPhi Biosciences Files Registration Statement for Public Offering of Shares 24

AmpliPhi Biosciences Raises USD10.6 Million in Public Offering of Shares 25

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares and Warrants 27

AmpliPhi BioSciences Raises USD5 Million in Public Offering of Shares and Warrants 29

AmpliPhi BioSciences Raises USD13 Million in Private Placement of Shares 31

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 18 Million 32

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 7 Million 33

Debt Offering 35

Ampliphi Biosciences Completes Private Placement Of Notes For USD 0.5 Million 35

Acquisition 36

AmpliPhi Biosciences Completes Acquisition Of Special Phage, Developer Of Anti-Bacterial Therapies 36

AmpliPhi Biosciences Corp-Key Competitors 37

AmpliPhi Biosciences Corp-Key Employees 38

AmpliPhi Biosciences Corp-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Aug 09, 2018: AmpliPhi Biosciences reports second quarter 2018 financial results and business highlights 40

May 15, 2018: AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights 41

Mar 14, 2018: AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights 42

Nov 14, 2017: AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights 43

Aug 14, 2017: AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights 44

May 15, 2017: AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights 46

Mar 27, 2017: AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights 48

Corporate Communications 50

May 31, 2017: AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer 50

Jan 30, 2017: AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer 51

Government and Public Interest 52

Sep 06, 2017: AmpliPhi Biosciences Announces Receipt of USD 2.0 Million R&D Tax Incentive 52

Product News 53

01/03/2018: AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 53

Clinical Trials 54

Sep 11, 2017: AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus 54

Apr 17, 2017: AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal 55

Apr 04, 2017: AmpliPhi Biosciences Presents Clinical and Preclinical Data of Pipeline Program AB-SA01 at Two Scientific Conferences 56

Other Significant Developments 57

Dec 14, 2017: AmpliPhi Biosciences Provides Corporate and Strategic Update 57

May 01, 2017: AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AmpliPhi Biosciences Corp, Deals By Therapy Area, 2012 to YTD 2018 9

AmpliPhi Biosciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

AmpliPhi Biosciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AmpliPhi Biosciences Acquires Certain Bacteriophage Assets from Novolytics 13

AmpliPhi Biosciences to Enter into Agreement with WSLHD and Westmead Institute for Medical Research 14

AmpliPhi Biosciences Enters into Cooperative Research and Development Agreement with US Department of Veterans 15

AmpliPhi Biosciences Enters into Agreement with University of Adelaide 16

AmpliPhi BioSciences Enters Into R&D Agreement With U.S. Army Medical Research and Materiel Command And Walter Reed Army Institute of Research 17

AmpliPhi Biosciences Enters into License Agreement with Takara Bio 18

AmpliPhi Enters into Licensing Agreement with University of Leicester 19

AmpliPhi Biosciences Raises USD6.8 Million in Public Offering of Shares 20

AmpliPhi Biosciences Raises USD3 Million in Private Placement of Shares 22

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares 23

AmpliPhi Biosciences Files Registration Statement for Public Offering of Shares 24

AmpliPhi Biosciences Raises USD10.6 Million in Public Offering of Shares 25

AmpliPhi Biosciences Raises USD4 Million in Public Offering of Shares and Warrants 27

AmpliPhi BioSciences Raises USD5 Million in Public Offering of Shares and Warrants 29

AmpliPhi BioSciences Raises USD13 Million in Private Placement of Shares 31

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 18 Million 32

AmpliPhi Biosciences Completes Private Placement Of Shares For USD 7 Million 33

Ampliphi Biosciences Completes Private Placement Of Notes For USD 0.5 Million 35

AmpliPhi Biosciences Completes Acquisition Of Special Phage, Developer Of Anti-Bacterial Therapies 36

AmpliPhi Biosciences Corp, Key Competitors 37

AmpliPhi Biosciences Corp, Key Employees 38

AmpliPhi Biosciences Corp, Other Locations 39

AmpliPhi Biosciences Corp, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AmpliPhi Biosciences Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.